ArticleFrontiers in pharmacology2020
Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis.Frontiers in pharmacology · 2022Pooled it
- Forecasting the Biological Effect of PEGylated-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach.Pharmaceutical research · 2026Article
- Cellular senescence of renal tubular epithelial cells in diabetic kidney disease: emerging mechanisms and targeted interventions.Frontiers in cell and developmental biology · 2026Review
- Jian-Pi-Yi-Shen formula improves kidney function by regulating gut microbiome in rats with chronic kidney disease.Frontiers in cellular and infection microbiology · 2025Article
- The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study.Inflammopharmacology · 2024Article
- Network pharmacology and multi-omics validation of the Jianpi-Yishen formula in the treatment of chronic kidney disease.Frontiers in immunology · 2024Article
- Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial.Frontiers in endocrinology · 2024Article
- Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3-4: a retrospective cohort study.Frontiers in medicine · 2024Article
- The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy --protocol of a multicenter, randomized control trial (SQ-AUTUMN).BMC complementary medicine and therapies · 2023Article
- Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients.Inflammopharmacology · 2022Article
- Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms.Frontiers in pharmacology · 2022Review
- Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway.BMC complementary medicine and therapies · 2021Article
- Uncovering Bupi Yishen Formula Pharmacological Mechanisms Against Chronic Kidney Disease by Network Pharmacology and Experimental Validation.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 20 institutions in 3 countries.
Wei MaoGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Nizhi YangGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Lei ZhangGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Chuang LiGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yifan WuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Wenwei OuyangDepartment of Global Public Health, Karolinska Institute, Stockholm, Sweden.
Peng XuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Chuan ZouGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Chunpeng PeiThe First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Ha'erbin, China.
Wei ShiThe First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China.
Jihong ZhanThe First Affiliated Hospital of Guiyang University of Traditional Chinese Medicine, Guiyang, China.
Hongtao YangFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Hongyu ChenHangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.
Xiaoqin WangHubei Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.
Yun TianShanxi Hospital of Traditional Chinese Medicine, Xi'an, China.
Fang YuanThe Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Wei SunJiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China.
Guoliang XiongShenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Ming ChenThe Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jianguo GuanLiu Zhou Traditional Chinese Medical Hospital, Liuzhou, China.
Shuifu TangThe First Affiliated Hospital of Guangdong University of Chinese Medicine, Guangzhou, China.
Chunyan ZhangYunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China.
Yuning LiuDongzhimen Hospital to Beijing University of Chinese Medicine, Beijing, China.
Yueyi DengLonghua Hospital Affiliated to Shanghai University of Traditional Chinese, Shanghai, China.
Qizhan LinGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Fuhua LuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Weihong HongZhu Hai Hospital of Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, China.
Aicheng YangThe Affiliated Jiang men Traditional Chinese Medicine Hospital, Jinan University, Jiangmen, China.
Jingai FangThe First Affiliated Hospital to Shanxi Medical University, Taiyuan, China.
Jiazhen RaoGuangzhou Hospital of Traditional Chinese Medicine, Guangzhou, China.
Lixin WangGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Kun BaoGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Feng LinXinhui Hospital of Traditional Chinese Medicine, Jiangmen, China.
Yuan XuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhaoyu LuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guobin SuDepartment of Global Public Health, Karolinska Institute, Stockholm, Sweden.
La ZhangRoyal Melbourne Institute of Technology, Melbourne, VIC, Australia.
David W JohnsonDepartment of Nephrology, Princess Alexandra Hospital, Brisbane, Australia, University of Queensland, Brisbane, Australia, Translational Research Institute, Brisbane, Australia.
Daixin ZhaoGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Haijing HouGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Lizhe FuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xinfeng GuoGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Lihong YangGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xindong QinGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Zehuai WenGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xusheng LiuGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNAffiliated Hospital of Liaoning University of Traditional Chinese Medicine · CNChengdu University of Traditional Chinese Medicine · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CNFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNGuangxi University of Chinese Medicine · CNGuiyang University · CNHangzhou Hospital of Traditional Chinese Medicine · CNHubei University of Chinese Medicine · CNJiangsu Province Hospital · CNJinan University · CNKarolinska Institutet · SELonghua Hospital Shanghai University of Traditional Chinese Medicine · CNPrincess Alexandra Hospital · AUShanxi Medical University · CNShanxi Province Hospital of Traditional Chinese Medicine · CNShenzhen Pingle Orthopedic Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic CKD4. This trial was a multicenter, double-blind, double-dummy, randomized controlled trial that was carried out from 11-08-2011 to 07-20-2015. Patients were assigned (1:1) to receive either BYF or losartan for 48 weeks. The primary outcome was the change in the slope of the estimated glomerular filtration rate (eGFR) over 48 weeks. The secondary outcomes were the composite of end-stage kidney disease, death, doubling of serum creatinine, stroke, and cardiovascular events. A total of 567 patients were randomized to BYF (
Indexed as
chronic kidney diseaseglomerular filtration ratelosartanrandomized controlled trialtraditional Chinese medicine
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.